Clinical Trial

Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 29, 2021 (before its estimated April 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, open,multicenter, randomized controlled phase III clinical trial. In patients with LS-SCLC who achieve remission after first-line chemoradiotherapy, the efficacy and safety of PCI or MRI surveillance is evaluated and analyzed. PCI is performed in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. MRI surveillance alone (delaying radiation until the actual brain metastasis) may be not inferior to PCI.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-03-31; most recent amendment 2021-04-28.
Status change: Not Yet Recruiting → Recruiting 2021-04-26
Trial Details
NCT Number NCT04829708
Lead Sponsor Shandong Cancer Hospital and Institute
Conditions Limited Stage Small Cell Lung Cancer
Enrollment 534 participants
Start Date 2021-04-26
Primary Completion 2026-04-15 (estimated)
Study Completion 2028-04-15 (estimated)
Updated on ClinicalTrials.gov 2021-04-29